These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33485919)

  • 1. APOL1, Black Race, and Kidney Disease: Turning Attention to Structural Racism.
    Cerdeña JP; Tsai J; Grubbs V
    Am J Kidney Dis; 2021 Jun; 77(6):857-860. PubMed ID: 33485919
    [No Abstract]   [Full Text] [Related]  

  • 2. Introduction: APOL1-Associated Kidney Disease.
    Pollak MR
    Semin Nephrol; 2017 Nov; 37(6):489. PubMed ID: 29110755
    [No Abstract]   [Full Text] [Related]  

  • 3. Worldwide Frequencies of APOL1 Renal Risk Variants.
    Nadkarni GN; Gignoux CR; Sorokin EP; Daya M; Rahman R; Barnes KC; Wassel CL; Kenny EE
    N Engl J Med; 2018 Dec; 379(26):2571-2572. PubMed ID: 30586505
    [No Abstract]   [Full Text] [Related]  

  • 4. APOL1 G2 risk allele-clarifying nomenclature.
    Zhang Z; Hao K; Ross MJ; Murphy B; Menon MC
    Kidney Int; 2017 Aug; 92(2):518-519. PubMed ID: 28709608
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.
    Reidy KJ; Hjorten R; Parekh RS
    Curr Opin Pediatr; 2018 Apr; 30(2):252-259. PubMed ID: 29406442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of
    Paranjpe I; Chaudhary K; Paranjpe M; O'Hagan R; Manna S; Jaladanki S; Kapoor A; Horowitz C; DeFelice N; Cooper R; Glicksberg B; Bottinger EP; Just AC; Nadkarni GN
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):401-403. PubMed ID: 32079610
    [No Abstract]   [Full Text] [Related]  

  • 7. Nephropathy Progression in African Americans With a Family History of ESKD: Implications for Clinical Trials in APOL1-Associated Nephropathy.
    Freedman BI; Spainhour M; Hicks PJ; Turner J; Robertson J; Langefeld CD; Murea M; Divers J
    Am J Kidney Dis; 2019 Aug; 74(2):284-286. PubMed ID: 31076172
    [No Abstract]   [Full Text] [Related]  

  • 8. APOL1-Mediated Kidney Disease.
    Hopper T; Olabisi OA
    JAMA; 2024 May; 331(19):1668-1669. PubMed ID: 38662391
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Grams ME; Surapaneni A; Ballew SH; Appel LJ; Boerwinkle E; Boulware LE; Chen TK; Coresh J; Cushman M; Divers J; Gutiérrez OM; Irvin MR; Ix JH; Kopp JB; Kuller LH; Langefeld CD; Lipkowitz MS; Mukamal KJ; Musani SK; Naik RP; Pajewski NM; Peralta CA; Tin A; Wassel CL; Wilson JG; Winkler CA; Young BA; Zakai NA; Freedman BI
    J Am Soc Nephrol; 2019 Oct; 30(10):2027-2036. PubMed ID: 31383730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein L1 and Kidney Disease in African Americans.
    Friedman DJ; Pollak MR
    Trends Endocrinol Metab; 2016 Apr; 27(4):204-215. PubMed ID: 26947522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Expanding Role of APOL1 Risk in Chronic Kidney Disease and Cardiovascular Disease.
    Estrella MM; Parekh RS
    Semin Nephrol; 2017 Nov; 37(6):520-529. PubMed ID: 29110759
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Friedman DJ; Pollak MR
    Annu Rev Physiol; 2020 Feb; 82():323-342. PubMed ID: 31710572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions.
    Young BA; Blacksher E; Cavanaugh KL; Freedman BI; Fullerton SM; Kopp JB; Umeukeje EM; West KM; Wilson JG; Burke W;
    Am J Nephrol; 2019; 50(4):303-311. PubMed ID: 31480040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOL1 risk variants and kidney disease: what we know so far.
    Siemens TA; Riella MC; Moraes TP; Riella CV
    J Bras Nefrol; 2018; 40(4):388-402. PubMed ID: 30052698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOL1 and kidney disease: new insights leading to novel therapies.
    Freedman BI
    Am J Kidney Dis; 2015 Jul; 66(1):9-11. PubMed ID: 26111904
    [No Abstract]   [Full Text] [Related]  

  • 16. Joint Associations of Maternal-Fetal APOL1 Genotypes and Maternal Country of Origin With Preeclampsia Risk.
    Hong X; Rosenberg AZ; Zhang B; Binns-Roemer E; David V; Lv Y; Hjorten RC; Reidy KJ; Chen TK; Wang G; Ji Y; Simpson CL; Davis RL; Kopp JB; Wang X; Winkler CA
    Am J Kidney Dis; 2021 Jun; 77(6):879-888.e1. PubMed ID: 33359152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1.
    Lertdumrongluk P; Streja E; Rhee CM; Moradi H; Chang Y; Reddy U; Tantisattamo E; Kalantar-Zadeh K; Kopp JB
    Cardiorenal Med; 2019; 9(4):212-221. PubMed ID: 30995638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOL1 Genotyping in Potential African American Living Kidney Donors: Utility and Cost-Effectiveness.
    Gudsoorkar P; Anand M; Abu Jawdeh BG
    Am J Nephrol; 2020; 51(2):116-118. PubMed ID: 31940609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.
    Freedman BI; Langefeld CD; Murea M; Ma L; Otvos JD; Turner J; Antinozzi PA; Divers J; Hicks PJ; Bowden DW; Rocco MV; Parks JS
    Nephrol Dial Transplant; 2011 Nov; 26(11):3805-10. PubMed ID: 21931123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOL1 and kidney disease.
    Pollak MR; Genovese G; Friedman DJ
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):179-82. PubMed ID: 22257798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.